Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus in women with recurrent implantation failure
IRCT20171007036623N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2017
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus in Recurrent Implantation Failure (RIF), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Gene expression of P53 in endometrial sample, Gene expression of IL-10 in endometrial sample and 13 more. Started Dec 2017; status: completed.
02
Drugs
tacrolimus
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on IRCT20171007036623N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171007036623N1.